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Abstract: The novel wake-promoting agent modaﬁ  nil has been in use for the treatment of 
several sleep disorders for a few years and is now undergoing clinical trials for its use in the 
treatment of stimulant addiction, but its primary mechanism of action remains elusive. Previ-
ous laboratory studies have shown that modaﬁ  nil has antioxidative and neuroprotective effects, 
which have not previously been suggested to be related to its wake-promoting effects. However, 
recent research indicates that free radicals may be related to sleep induction as well as cellular 
damage, suggesting that a common target of action may mediate modaﬁ  nil’s ability to oppose 
both of these effects. In this review we summarize and discuss previously published research 
on modaﬁ  nil’s neural, cytoprotective, and cognitive effects, and we propose possible primary 
biochemical targets that could underlie the effects of modaﬁ  nil observed in these studies. We 
also suggest neurocognitive mechanisms responsible for modaﬁ  nil’s cognitive enhancing effects 
and its therapeutic potential in the treatment of stimulant addiction.
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Introduction 
In 1998 a unique drug for the treatment of narcolepsy was approved by the Food and 
Drug Administration for the narcolepsy armamentarium. Despite several years of pre-
clinical research, the mechanism of action of modaﬁ  nil was unknown. Almost a decade 
later there is a plethora of evidence showing that it is effective for treating several sleep 
disorders (Ballon and Feifel 2006), and there are ongoing clinical trials for its use in 
fatigue, cocaine addiction, attention deﬁ  cit disorder, depression, seasonal affective 
disorder, bipolar depression, nicotine addiction, and schizophrenia. Some preclinical 
evidence also indicates a possible use in the treatment of neurodegenerative diseases. 
Most research on modaﬁ  nil’s wake-promoting mechanism has focused on monoami-
nergic effects showing modaﬁ  nil stimulates histamine (HA), norepinephrine (NE), 
serotonin (5-HT), dopamine (DA), and orexin systems in the brain, but researchers 
have not been able to isolate a single site of action or locate major receptor binding. 
Modaﬁ  nil’s mechanism of action (MOA) remains elusive as pointed out in a recent 
editorial on modaﬁ  nil entitled, “Modaﬁ  nil: a drug in search of a mechanism” (Saper 
and Scammell 2004). There has also been research into the neuroprotective actions 
of modaﬁ  nil, which we propose to be related to its alerting effects. We selectively 
review a number of preclinical and clinical papers relevant to modaﬁ  nil’s MOA. We 
conclude with contemplations of MOA, particularly as it pertains to modaﬁ  nil’s effects 
in addictive disorders.
Modaﬁ  nil preclinical studies
General medicine studies
Mignot et al (1994) published one of the ﬁ  rst searches to ﬁ  nd a receptor to which 
modaﬁ  nil was shown to have binding a afﬁ  nity using binding assays for the following Neuropsychiatric Disease and Treatment 2007:3(3) 350
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receptors and binding sites: adenosine, dopamine, GABA, 
serotonin, NMDA, kainite, quisqualate, glycine, benzo-
diazepine, phencyclidine, MK-801, angiotensin, Arg-
vasopressin, bombesin, cholecystokinin, neuropeptide 
Y, substance K, substance P, neurotensin, somatostatin, 
vasoactive intestinal peptide, atrial natriuretic factor 1, epi-
dermal growth factor, nerve growth factor, calcium channels, 
chloride channels, low conduction K+ channels, and second 
messenger systems; and the following uptake channels: 
adenosine, choline, GABA, dopamine, norepinephrine, and 
serotonin. It was found that modaﬁ  nil was weakly selective 
for the dopamine transporter, binding to this cell-membrane 
protein and not at all to any other receptors tested. They were 
skeptical that modaﬁ  nil might act by blocking this trans-
porter, and they pointed out that modaﬁ  nil has more potent 
behavioral effects than some molecules that bind with a much 
greater afﬁ  nity to the dopamine reuptake transporter.
Simon et al (1995) compared the locomotor effects of 
modaﬁ  nil with dexamphetamine in rodents in conjunction 
with the D2 antagonist haloperidol, the D1 antagonist SCH 
23390, alpha-methyl-para-tyrosine, the anti-monoaminergic 
agent reserpine, and L-DOPA-benserazide. They found that 
while behavioral effects of amphetamine could be suppressed 
by haloperidol, SCH 23390, or alpha-methyl-para-tyrosine, 
modaﬁ  nil’s behavioral effects were not blocked by these 
agents at most doses. The administration of a very high dose 
of SCH 23390 was able to reduce the locomotor effects of 
modaﬁ  nil. Amphetamine was able to reverse the akinesia 
induced by the anti-monoaminergic agent reserpine, while 
modaﬁ  nil showed no signiﬁ  cant locomotor effect in reser-
pine-treated animals. A ﬁ  nal in vitro study of dopaminergic 
synaptosomes showed that while amphetamine caused spon-
taneous dopamine release, modaﬁ  nil had no such effect.
Tanganelli et al (1995) looked at modaﬁ  nil’s effects on 
cortical GABA and monoamine levels through post mortem 
analysis using high performance liquid chromatography in 
the brains guinea pigs and rats sacriﬁ  ced shortly after drug 
administration. Some were lesioned with the neurotoxin 
5,7-dihydroxytryptamine (selective for serotonin neurons) 
and given the α1 receptor antagonist prazosin. They found 
that modaﬁ  nil by itself decreased cortical GABA, but in rats 
treated with 5,7-dihydroxytryptamine modaﬁ  nil increased 
cortical GABA, indicating that modaﬁ  nil decreases cortical 
GABA through a serotonin mediated pathway. They also 
noted that the administration of prazosin in conjunction 
with 5,7-dihydroxytryptamine could block the increase in 
GABA, showing that modaﬁ  nil increases cortical GABA 
through a norepinephrine mediated pathway. To examine 
the direct effects of modaﬁ  nil on GABA uptake and release 
they administered modaﬁ  nil to rat brain slices and found 
that modaﬁ  nil did not directly affect GABA uptake, GABA 
release, or glutamate decarboxylase activity. 
Lin et al (1996) examined fos immunoreactivity in 26 
brain sites of cats after the administration of amphetamine, 
methylphenidate, or modaﬁ  nil. They found that modaﬁ  nil 
induced very little fos-like immunoreactivity in the cortex, 
but it did induce fos labeling in the anterior hypothalamus 
and nearby areas, in contrast to amphetamine and meth-
ylphenidate. They also noted no fos labeling in the basal 
forebrain, thalamus, posterior hypothalamus, or the midbrain 
tegmentum as a result of modaﬁ  nil administration.
Ferraro et al (1996) in the ﬁ  rst of a series of papers about 
modaﬁ  nil’s actions showed using in vivo microdialysis in rats 
that modaﬁ  nil decreases GABA in the medial preoptic area 
of the hypothalamus and the posterior hypothalamus. They 
found that the 5-HT3 receptor antagonist MDL72222 alone 
was able to attenuate this effect almost as much as the general 
serotonin antagonist methysergide, indicating that modaﬁ  nil 
worked to decrease GABA partly through a serotonergic 
pathway mediated primarily by the 5-HT3 receptor.
Bettendorf et al (1996) used high performance liquid 
chromatography to study cortical glutamate and GABA 
levels of sacriﬁ  ced rats after modaﬁ  nil-induced paradoxical 
sleep deprivation and non-pharmacological paradoxical sleep 
deprivation using the platform method, in which the paralysis 
of REM sleep causes rats to make contact with water and 
awaken. They found that modaﬁ  nil did not increase corti-
cal glutamate levels in 2 or in 7 hours of sleep deprivation. 
They also found that non-pharmacologic sleep deprivation 
did not increase cortical glutamate in a similar time period 
(5 hours), but it did increase cortical glutamate after 12 
and 24 hours (there were no reports of data collected from 
modaﬁ  nil-treated mice after 12 or 24 hours of sleep depriva-
tion). These results suggested that modaﬁ  nil does not increase 
cortical glutamate in the ﬁ  rst few hours after administration, 
and modaﬁ  nil appears to affect cortical glutamate levels no 
differently than non-pharmacological sleep deprivation in 
the ﬁ  rst few hours.
Ferraro et al (1997b) examined the in vivo dopamine 
and GABA levels of the nucleus accumbens in rats given 
modaﬁ  nil, and they found that modaﬁ  nil had a very minor 
effect on nucleus accumbens dopamine, but it led to a sub-
stantial reduction in GABA release. That same year, this 
group published another paper which they described an 
experiment examining GABA and glutamate in the thalamus 
and hippocampus, ﬁ  nding that modaﬁ  nil increased glutamate Neuropsychiatric Disease and Treatment 2007:3(3) 351
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in these brain areas, but did not alter GABA levels in these 
locations (Ferraro et al 1997a).
Edgar and Seidel (1997) investigated the effects of 
modaﬁ  nil on sleep-wake EEG and locomotor activity in live 
rats in comparison with the effects of methamphetamine. 
They found that modaﬁ  nil increased locomotor activity 
only slightly unlike methamphetamine which induced pro-
found increases in locomotor activity. They also found that 
modaﬁ  nil and methamphetamine increased wake time, but 
modaﬁ  nil produced more consolidated periods of wakeful-
ness, and modaﬁ  nil did not cause rebound hypersomnolence 
as opposed to methamphetamine. From these results they 
suggested that modaﬁ  nil is more effective in inhibiting the 
sleep drive than methamphetamine.
Ferraro et al (1998) studied the effects of modaﬁ  nil on 
GABA in the striatum, pallidum, and substantia nigra of 
conscious rats. They found that modaﬁ  nil reduced GABA 
in the pallidum and striatum, but not in the substantia nigra. 
They also found that modaﬁ  nil does not increase glutamate 
except in the substantia nigra at very high doses. They 
concluded that via GABA reductions, modaﬁ  nil is able to 
improve motor activity.
Engber et al (1998) measured glucose utilization with 
2-deoxyglucose autoradiography in the brains of rats given 
modaﬁ  nil, and they found that modaﬁ  nil increased glucose 
utilization in the thalamus, hippocampus, subiculum, and the 
amygdala, but they noted that much of the glucose utiliza-
tion in the brain may be in the mitochondria of axons and 
dendrites rather than cell somas.
Ferraro et al (1999) using in vivo microdialysis and post 
mortem high performance liquid chromatography found that 
modaﬁ  nil increases extracellular glutamate in the medial 
preoptic and posterior areas of the hypothalamus, but the 
local application of the GABAA receptor antagonist bicucul-
line, which raised basal glutamate levels, prevented a further 
increase in glutamate from modaﬁ  nil. Administration of 
the glutamate uptake blocker L-trans-PDC with modaﬁ  nil 
was also done, which showed that even after extracellular 
glutamate levels had been increased by glutamate transport 
blockade, modaﬁ  nil was still able to increase extracellular 
glutamate. These results suggested to the researchers that 
a reduction in the GABAergic tone of the medial preoptic 
area and of the posterior hypothalamus mediates modaﬁ  nil’s 
glutamatergic effect in these areas. 
Perez de la Mora et al (1999), seeking to ﬁ  nd the man-
ner in which modaﬁ  nil could change glutamate and GABA 
levels of the hypothalamus, studied the effect of modaﬁ  nil on 
glutamate and GABA synthesis in ex vivo and in vitro slices 
of the rat hypothalamus, by measuring tritium incorporation 
into glutamate and GABA and found no effect of modaﬁ  nil 
on the synthesis of these neurotransmitters.
Sebban et al published 2 studies in 1999 using eletroen-
cephalography in live rats to test modaﬁ  nil in conjunction 
with the general dopamine receptor antagonist clozapine 
or the selective D2 antagonist raclopride. They found that 
modaﬁ  nil bolstered the EEG synchronization caused by 
raclopride, and it was able to attenuate in both cortices the 
synchronizing effects of clozapine, which has an α1 adren-
ergic receptor antagonist properties. However, modaﬁ  nil by 
itself causes decreased power of the frequencies in the 6–18 
Hz range of the EEG. The α1 agonist cirazoline displayed a 
very different effect on the EEG spectral powers decreasing 
power at 3, 5–6, 8, and 13 Hz and increasing power at 1–2 
and 19–30 Hz (Sebban et al 1999a, b).
Chemelli et al (1999) examined fos-reactivity in orexin 
neurons of mice given modaﬁ  nil before sacriﬁ  ce and found 
a substantially greater activation of orexin neurons with 
modaﬁ  nil than with placebo.
Scammell et al (2000) administered modaﬁ  nil to live rats, 
sacriﬁ  ced them two hours later, and analyzed the brain slices 
using immunohistochemistry. They found fos reactivity in 
the tuberomamillary nucleus and in orexin neurons.
Ferraro et al (2000) studied cortical serotonin release in 
vivo and vitro in rat brains. They found that modaﬁ  nil is able 
to enhance serotonin release, but it does not cause serotonin 
release or reuptake on its own and suggested that modaﬁ  nil 
increased electro-secretory coupling in neurons.
Wisor et al (2001) measured behavioral effects of narco-
leptic dogs and of dopamine transporter knockout rats using 
EEG, EMG, wheel running (for the rats), and in vivo micro-
dialysis in the caudate nucleus (in the dogs). They found that 
modaﬁ  nil increased dopamine in the caudate and promoted 
arousal in the absence of orexin receptors, but modaﬁ  nil had 
little effect in dopamine transporter-null rats, who without 
modaﬁ  nil already spent substantially more time awake and 
a little more time wheel running than normal mice.
de Saint Hilaire et al (2001) measured arousal with EEG 
and local brain monoaminergic levels using microdialysis in 
the prefrontal cortex and the ventromedial preoptic area of 
the hypothalamus in rats given modaﬁ  nil. They found that 
cortical 5-HT, DA, and NE increased in the hour following 
modaﬁ  nil administration, and 5-HT remained high for several 
hours. In the hypothalamus only NE release was enhanced 
by modaﬁ  nil.
Ferraro et al (2001) measured tritiated serotonin efﬂ  ux 
from modaﬁ  nil in vitro on serontonergic synaptosomes Neuropsychiatric Disease and Treatment 2007:3(3) 352
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and cortical slices and found that modaﬁ  nil was not able to 
increase spontaneous 5-HT efﬂ  ux or K+-evoked 5-HT efﬂ  ux 
in synaptosomes, but modaﬁ  nil was able to increase electri-
cally evoked 5-HT efﬂ  ux in cortical slices, and this effect 
was enhanced by serotonin uptake blockade.
Stone et al (2002) showed that the α1A adrenergic recep-
tor antagonist WB4101 and the α1D antagonist BMY7378 
had little effect on the increase in motor activity caused by 
modaﬁ  nil, but terazosin, which blocks α1A, α1D, and α1B 
receptors signiﬁ  cantly attenuated this effect. Furthermore, 
modaﬁ  nil had very small effects on gross movement in α1B 
receptor knockout mice. Together these results suggest that 
the α1B adrenergic receptor mediates modaﬁ  nil’s locomotor 
effects. They point to a previous study suggesting that α1B 
relates to movement but is not antisedative, so this pathway 
is involved in the motor but not the wake-promoting effects 
of modaﬁ  nil.
Stone et al (2002) also reported the effects of stress on 
modaﬁ  nil’s stimulation of increased gross movement in live 
rats, some of whom were pretreated with corticosterone or 
dexamethasone. They noted that stress decreased overall 
gross movement, an effect attenuated by corticosterone pre-
treatment, and stress also decreased the modaﬁ  nil induced 
boost in gross movement. However, pretreatment with cor-
ticosterone or dexamethasone mitigated the impact of stress 
on modaﬁ  nil’s movement effects. The authors comment that 
these results support the hypothesis that stress desensitizes 
or inhibits α1 adrenoreceptors and corticosterone pretreat-
ment attenuates this effect, though the exact mechanism of 
this effect was not clear.
Ferraro et al (2002) measured serotonin levels in 
rats using in vivo microdialysis in the: frontal cortical, 
amygdaloid, dorsal raphe, medial preoptic, and posterior 
hypothalamic areas, and they found that modaﬁ  nil stimulates 
the serotonergic system of the cortex, DRN, and amygdala 
at low doses, but only at high doses did it promote 5-HT 
release in the hypothalamus.
Ishizuka et al (2003) measured brain histamine 
release using microdialysis in vivo in rats given modaﬁ  nil 
intraperitoneally, intraventricullarlry, or directly into the 
tuberomamillary nucleus (TMN) and found that modaﬁ  nil 
had no effect on HA when administered directly into the TMN 
neurons, and had the fastest effect on histamine when given ip, 
indicating that modaﬁ  nil did not directly target the TMN.
Gallopin et al (2004) recorded VLPO neuron electro-
physiology in vivo in rats given modaﬁ  nil in conjunction with 
monoamines, clonidine, L-phenylephrine, yohimbine, nisox-
etine, carbachol, CNQX, AP-5, bicuculline, or TTX. They 
found that modaﬁ  nil promoted wakefulness by inhibiting 
the VLPO and this was dependent upon noradrenergic inhibi-
tion of VLPO neurons via an α2 adrenergic receptor.
Della Marca et al (2004) studied sensory evoked poten-
tials in humans given modaﬁ  nil and found that modaﬁ  nil 
changed the subcortical electrophysiological oscillatory 
pattern in sensory evoked potentials. They concluded that the 
cortical effects of modaﬁ  nil are the result of reduced GABA 
transmission in the cortex.
Willie et al (2005) studied the effects of modaﬁ  nil in rats 
congenitally missing both alleles for orexin and noted that 
modaﬁ  nil was actually able to promote wakefulness better 
in these rats than in wild-type litter mates, but it was not 
able to promote alertness as well in the orexin-null rats as 
in wild-type mice. Modaﬁ  nil was also unable to reduce the 
number of direct transitions to REM sleep in the orexin-null 
mice. These results indicate that the orexinergic system is 
involved in modaﬁ  nil’s stimulant effects, but it is not the 
primary center of action or the only pathway through which 
modaﬁ  nil works.
Wisor and Eriksson (2005) studied the effects of modaﬁ  nil 
in conditions of altered dopamine and norepinephrine levels. 
They found that DSP-4 administration, which eliminates 
neuron projections bearing norepinephrine transporters, 
did not hinder the wake-promoting effects of modaﬁ  nil in 
rats, but the α1 adrenergic antagonist terazosin was able to 
prevent the effects of modaﬁ  nil in DSP-4 treated mice. They 
also found that the dopamine autoreceptor agonist quinpirole 
attenuated the effects of modaﬁ  nil in DSP-4 treated mice, 
indicating a role for dopamine in modaﬁ  nil’s wake-promoting 
effects. As such, the authors suggested that modaﬁ  nil worked 
through an increase in dopamine tone and dopamine’s stimu-
lation of the α1 adrenergic receptor.
Hou et al (2005) studied the autonomic effects of 
modaﬁ  nil in humans. They found that modaﬁ  nil affects the 
locus coeruleus, which mediates pupil diameter and arousal, 
but it does not affect other autonomic functions, which are 
controlled by noreadrenergic control centers (A1 – A5) 
located outside of the locus coeruleus.
Ferraro et al (2005) studied the effects of modaﬁ  nil in vivo 
in rats and found that by itself it did not increase serotonin 
transmission, but it did cause an increase in effects of classic 
serotonin uptake inhibitors given at sub threshold doses.
Madras et al (2006) in a recent paper demonstrated in 
vivo binding of modaﬁ  nil to striatal DAT and thalamic 
NET in rhesus monkeys using PET imaging. The investiga-
tors compared binding of the DAT probe [11C]CFT and the 
NET probe [11C]MeNER in the absence of modaﬁ  nil with Neuropsychiatric Disease and Treatment 2007:3(3) 353
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the binding of these probes in the presence of modaﬁ  nil to 
calculate modaﬁ  nil’s occupancy of DAT and NET in vivo. 
Finding that modaﬁ  nil occupied these sites, the investigators 
examined modaﬁ  nil’s effects compared with those of methyl-
phenidate and benztropine on DAT and NET transporters in 
vitro. They found that modaﬁ  nil was a weak inhibtor of the 
NET and that modaﬁ  nil’s ability to effect DA reuptake via 
the DAT was about a one-hundredth that of methylphenidate 
and about a tenth that of benztropine. The authors conclude 
that while modaﬁ  nil probably exerts its effects via more than 
one mechanism, modaﬁ  nil’s occupancy of the DAT prob-
ably plays a role in its pharmacological effects that should 
be further investigated.
Discussion of sleep and modaﬁ  nil’s 
neurotransmitter effects
Theories regarding the physiology of sleep in recent years 
have focused on a two-process model of sleep in which the 
sleep/wake system is governed by both a circadian process 
affected by exposure to light and a homeostatic process 
affected by physiologic demand for sleep (Pace-Schott 
and Hobson 2002). The effect of sleep deprivation to 
increase the sleep drive is mediated by the homeostatic 
process, which appears to be largely controlled by the 
basal forebrain. This region of the brain contains excitatory 
cholinergic cortical projections and inhibitory GABAergic 
projections to the sleep-promoting VLPO (Strecker et al 
2000; Markov and Goldman 2006). This process is also 
believed to be regulated by the inhibitory neuromodulator 
adenosine, which increases during wakefulness and pro-
duces sleep pressure by decreasing basal forebrain activity 
resulting in a disinhibition of VLPO activity and a decrease 
in ascending cholinergic tone. For reviews see Saper et 
al (2001), Mignot et al (2002), Pace-Schott and Hobson 
(2002), Markov and Goldman (2006).
Though it is not fully known which processes cause 
an animal to be awake or asleep, research has shown that 
a number of systems are characteristically active during 
wakefulness and therefore suspected to play a role in main-
tenance of vigilance. The monoaminergic system, especially, 
has received attentention for its activity in the sleep wake 
cycle. It has been observed that histamine, serotonin, and 
norepinephrine tone is directly related to arousal state, and 
that neurons releasing these chemicals are almost silent 
in REM sleep. Relatively recently the peptide orexin was 
discovered in neurons of the lateral hypothalamus and sub-
sequently shown to play an important role in the maintenance 
of vigilance (Jones 2005). 
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Modaﬁ  nil has shown the ability to increase HA, NE, 
5-HT, and DA levels in the brain (Ferraro et al 2000; de Saint 
Hilaire et al 2001; Ferraro et al 2002; Madras et al 2006), 
but modaﬁ  nil almost certainly exerts some of these effects in 
part via an indirect mechanism or an upstream site of action. 
Though the recent paper by Madras and colleagues indicates 
that modaﬁ  nil has some physiologically signiﬁ  cant effect on 
the DAT and possibly the NET, not all of modaﬁ  nil’s effect 
are likely mediated by this particular mechanism, as the 
investigators themselves suggest. In vitro studies indicate 
that modaﬁ  nil does not directly stimulate 5-HT release, but 
it does enhance 5-HT tone from neurons or synaptosomes 
stimulated via other methods (Ferraro et al 2000; Ferraro 
et al 2001; Ferraro et al 2005). In vivo studies show ana-
tomically selective neurochemical effects of modaﬁ  nil on 
monoaminergic systems (de Saint Hilaire et al 2001; Ferraro 
et al 2002), and, notably, while modaﬁ  nil increases TMN 
fos expression (Scammell et al 2000) and HAergic tone it 
is not able to exert this effect when administered directly 
into the TMN (Ishizuka et al 2003). Additionally, despite 
the importance of orexin in the maintenance of vigilance, 
modaﬁ  nil is capable of promoting wakefulness in the absence 
of an orexin receptors or orexinergic neurons (Wisor et al 
2001; Willie et al 2005). 
Modaﬁ  nil’s effects on glutamate appear to be quite var-
ied by brain region. It was shown that modaﬁ  nil increased 
extracellular glutamate in the medial preoptic and posterior 
hypothalamus and that this effect was due to the reduction in 
GABAergic tone mentioned previously (Ferraro et al 1996, 
1999). In the thalamus and hippocampus modaﬁ  nil also 
appeared to increase glutamate levels, but here it did not alter 
GABA tone (Ferraro et al 1997a). On the other hand it was 
observed that modaﬁ  nil did not signiﬁ  cantly increase gluta-
mate in the substantia nigra (except at very high doses), in the 
striatum, or in the pallidum (Ferraro et al 1998). The effect 
of modaﬁ  nil on cortical glutamate is unclear, as it has been 
reported that modaﬁ  nil increases cortical glutamate and that 
modaﬁ  nil does not signiﬁ  cantly increase cortical glutamate 
(Pierard et al 1995; Bettendorf et al 1996). The possibility 
that modaﬁ  nil alters GABA and glutamate synthesis rates was 
explored as possible explanation of modaﬁ  nil’s effects, and 
modaﬁ  nil exhibited no observable effect on these pathways 
(Perez de la Mora et al 1999).
Modaﬁ  nil’s effects on GABA appear to be more con-
sistent across brain regions than its effects on glutamate. 
Modaﬁ  nil does not appear to have much effect on GABA in 
the thalamus or hippocampus, but GABA levels were reduced 
by modaﬁ  nil in most brain regions studied: the cortex, medial 
preoptic area of the hypothalamus, posterior hypothalamus, 
nucleus accumbens, pallidum, and striatum, and this effect 
generally appears to be mediated by serotonin (Tanganelli 
et al 1995; Ferraro et al 1996, 1997a, b, 1998, 1999). Interest-
ingly, in one of these studies (Tanganelli et al 1995) destruc-
tion of serotonin neurons with a selective neurotoxin, did not 
simply block modaﬁ  nil’s GABA inhibiting effects but caused 
modaﬁ  nil to increase cortical GABA. It appears that in this 
study the GABAergic neurons were strongly inhibited by a 
serotonergic mechanism and weakly stimulated via a nor-
adrenergic pathway. If modaﬁ  nil enhances neurotransmitter 
release via increased electrosecretory coupling, then it would 
be expected that modaﬁ  nil would enhance GABA release 
upon removal of the serotonergic inhibitory inﬂ  uence.
Neuroprotective effects of modaﬁ  nil
Pierard et al (1995) measured the in vivo cortical pool 
of glutamate-glutamine, aspartate, inositol, and creatine-
phosphocreatine using 2D COSY H-NMR. They found that 
modaﬁ  nil increased the cortical pool of all of these substances 
and attributed modaﬁ  nil’s neuroprotective effects to its ability 
to increase creatine-phosphocreatine and its wake-promoting 
actions to the resultant increased metabolic activation.
Antonelli et al (1998) tested modaﬁ  nil’s neuroprotective 
effect with regard to glutamate cytotoxicity by measuring 
GABA release and GABA uptake in cultured rat cortical 
neurons. They found that unlike glutamate receptor antago-
nists, modaﬁ  nil was unable to fully prevent initial reductions 
in GABA release, but modaﬁ  nil was able to prevent the 
further reduction in GABA release over the following half 
hour that was seen in the cells exposed to glutamate but not 
modaﬁ  nil. Modaﬁ  nil also had no effect on GABA release 
or uptake in neurons not exposed to glutamate, indicating 
that modaﬁ  nil does not simply stimulate additional GABA 
release; rather it may help cells recover their neurosecretory 
coupling mechanism after glutamate exposure.
Jenner et al (2000) looked at the neuroprotective and 
anti-parkinsonian effects of modaﬁ  nil in monkeys treated 
with MPTP. In one study they found that the MPTP induced 
parkinsonism symptoms could be improved with modaﬁ  nil 
11 months after MPTP administration. In a second study 
they found that modaﬁ  nil administration with MPTP was 
unable to prevent initial locomotor effects of MPTP, but was 
able to restore locomotor activity within two weeks. More 
nigral neurons survived when modaﬁ  nil was administered 
in conjunction with MPTP. They concluded that modaﬁ  nil 
stimulates locomotor effects in already injured animals, and 
modaﬁ  nil is neuroprotective , but it does not effectively block Neuropsychiatric Disease and Treatment 2007:3(3) 355
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the DA transporter, for it is not able to prevent the initial 
effects of MPTP which enters the cell through the dopamine 
transporter to cause damage.
Xiao et al (2004) used post mortem examination of the 
brains of MPTP treated mice. They found that modaﬁ  nil 
reduced striatal GABA, increased the levels of reduced glu-
tathione in MPTP damaged neurons, and reduced levels of 
the lipid peroxidation product malodialdehyde. These results 
suggest that modaﬁ  nil exerts a neuroprotective effect through 
its ability to attenuate or prevent oxidative damage.
Discussion of modaﬁ  nil’s 
neuroprotective effects
In addition to modaﬁ  nil showing potent effects on the 
sleep/wake system, it is clear that modaﬁ  nil has noteworthy 
neuroprotective effects as well that involve some sort of 
antioxidative process. While these effects may be 
coincidental to modafinil’s wake-promoting effects, 
the role of the ATP breakdown product adenosine in 
homeostatic sleep regulation is at least suggestive that 
modaﬁ  nil’s neuroprotective effects are not irrelevant to 
the consideration of modaﬁ  nil’s wake-promoting effects. 
Because the primary site of action of modaﬁ  nil’s antioxidant 
effects remains elusive, we discuss some possible targets 
for future investigation here.
It is clearly a possibility that modaﬁ  nil could directly act 
on enzymes in the brain’s free-radical scavenging system (eg, 
glutathione peroxidase or superoxide dismutase) to directly 
reduce free-radical levels. Because, reactive oxygen species 
feed back positively on the mitochondrion to reduce ATP 
production and possibly enhance free radical production 
(Echtay et al 2002; Brookes et al 2004), such a mechanism 
could also account for modaﬁ  nil’s ability to increase the 
cortical creatine-phosphocreatine pool (Pierard et al 1995). 
It would be worth examining whether other known free-
radical reducing compounds have a similar effect on the 
creatine pool of the brain. 
The mitochondrion is the biggest producer of reactive 
oxygen species in the cell, and as such modafinil may 
target this organelle to directly inhibit free-radical produc-
tion and promote ATP production, which would tend to 
promote increases in creatine-phosphocreatine production. 
One good candidate for a site of action of modaﬁ  nil in 
the mitochondrion is cytochrome c or an enzyme that reacts 
with it. Cytochrome c functions in the mitochondrial electron 
transport chain normally to move electrons from complex 
III to complex IV to make water, but it is also capable of 
being released from the inner mitochondrial membrane 
and accepting electrons from hydrogen peroxide in the 
intermembrane space or superoxide generated by complex 
I (see Skulachev [1998] for review). Modaﬁ  nil may enhance 
cytochrome c’s ability to accept and donate electrons by 
allosteric modiﬁ  cation or a catalytic mechanism. Such a 
mechanism would directly reduce net hydrogen peroxide lev-
els and superoxide production and increase ATP production. 
The ability to accept electrons from superoxide at complex 
I would provide a direct mechanism for modaﬁ  nil’s ability 
to reduce MPTP-induced neuron death, which appears to be 
mediated by promoting superoxide production in complex 
I and inhibiting its normal activity. This mechanism would 
also involve reduced activity of the inhibitory KATP-channels 
that suppress neurotransmitter release and thereby account 
for increased neurotransmitter release.
Also noteworthy is the action of modaﬁ  nil on other 
cytochromes, particularly those of the cytochrome P450 
system, which is responsible for drug metabolism in the 
liver and appears to have a role in the brain (McFadyen 
et al 1998; Klose et al 1999; Voirol et al 2000; Gervasini 
et al 2001; Llerena et al 2003; Gervasini et al 2004). 
Modaﬁ  nil inhibits CYP2C19, and is a potent suppressor 
in hepatocytes of CYP2C9 (Robertson et al 2000), which 
itself has not yet been found to be present in the brain, but 
other cytochrome P450 enzymes including CYP2C enzymes 
have been found in the brain, and there is evidence for a 
role of brain CYP 2C9 speciﬁ  cally (Llerena et al 2003; 
Gervasini et al 2004). This particular member of the cyto-
chrome P450 family has been shown to be a functionally 
relevant source of reactive oxygen species in coronary 
artery ischemia and reperfusion injury, and inhibition of 
cytochrome P450 enzymes has been shown to reduce dam-
age in coronary artery ischemia and reperfusion (Fleming 
et al 2001; Granville et al 2004). As such CYP2C9 would 
likely produce physiologically relevant levels of reactive 
oxygen species in the brain if it is located there. It has also 
been proposed that CYP2C enzymes are involved in the 
metabolism of arachidonic acid in the brain and in altering 
the effects of neurotransmitters (Gervasini et al 2004), and 
the potential importance of CYP2C9 activity in brain func-
tion is further supported by the observation that CYP2C9 
genotypes may affect a person’s susceptibility to major 
depressive disorder (Llerena et al 2003). From these stud-
ies it is clear that modaﬁ  nil’s effect on cytochrome P450 
enzymes in the brain, especially CYP2C9, which modaﬁ  nil 
is already known to suppress, is worthy of further study.
Modaﬁ  nil’s suppression of brain CYP2C9 could explain 
modafinil’s ability to reduce reactive oxygen species Neuropsychiatric Disease and Treatment 2007:3(3) 356
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production. There is also the question of how modaﬁ  nil 
would suppress or inhibit CYP2C9 activity in the brain. It is 
possible that modaﬁ  nil could work through a direct intracel-
lular site of action to suppress CYP2C9, but it should also be 
mentioned that serotonin, which modaﬁ  nil has been shown 
to enhance or require the release of (Tanganelli et al 1995; 
Ferraro et al 1996, 2000, 2001, 2005), and epinephrine are 
inhibitors of CYP2C9 activity in hepatocytes (Gervasini 
et al 2001). Therefore, modaﬁ  nil could intracellularly inhibit 
CYP2C9 in the brain, thereby reducing reactive oxygen 
species levels and promoting better mitochondrial function. 
This could enhance serotonin release through greater avail-
ability of metabolic substrates, which would further inhibit 
CYP2C9, and modaﬁ  nil would exert its powerful wakening 
effects through this positive feedback loop potentiating its 
antioxidative and serotonergic effects. We chose to focus 
speciﬁ  cally on a potential mechanism of modaﬁ  nil involving 
CYP2C9 because of the tested cytochrome P450 enzymes, 
modaﬁ  nil has been shown to have the greatest effect on this 
particular enzyme (Robertson et al 2000), but this does not 
rule out the possibility of an effect mediated by other P450 
enzymes.
Anatomically speciﬁ  c regions of activation rather than 
neurochemical effects of modaﬁ  nil have also been explored 
in some studies (Lin et al 1996; Engber et al 1998; Chemelli 
et al 1999; Scammell et al 2000), but a particular brain region 
of action for modaﬁ  nil has not yet been determined. The anti-
oxidative basis of modaﬁ  nil’s stimulant effects proposed here 
would likely act in neurons throughout the brain, but there 
may be particular brain regions where this anti-oxidative 
effect most strongly exerts its wake-promoting inﬂ  uence. 
The basal forebrain is perhaps such a region, for it is here 
particularly that adenosine exerts its sleep promoting effects 
(Porkka-Heiskanen et al 1997; Alam et al 1999; Porkka-
Heiskanen et al 2000; Strecker et al 2000). Adenosine appears 
to be an endogenous sleep factor that increases while 
awake and induces sleepiness as its levels increase (Huston 
et al 1996; Strecker et al 2000), and the sleep-inducing 
effects of free radicals have been attributed at least in part to 
the consequent increases in extracellular adenosine (Ikeda 
et al 2005). As such, modaﬁ  nil may play an antioxidant role 
throughout the entire brain and modulate adenosine levels 
throughout the entire brain, but it is in the basal forebrain 
that a reduction in adenosine resulting from reduced reac-
tive oxygen species concentrations would have its greatest 
wake-promoting effects. In a previous study it was shown 
that modaﬁ  nil does not show fos-immunoreactivity in the 
basal forebrain (Lin et al 1996), and this is consistent with 
reduced levels of the inhibitory neuromodulator adenosine in 
this region of the brain, for adenosine increases c-fos expres-
sion in the basal forebrain (Basheer et al 1999).
Modaﬁ  nil human neurocognitive 
studies
EEG studies
EEG band deﬁ  nitions can vary somewhat among studies, 
and research indicates that alpha bands vary among individu-
als and with age. These EEG band deﬁ  nitions are speciﬁ  c 
to humans and are different in lower mammals (Klimesch 
1999).
Delta: 1–4 Hz
Theta: 4–7 Hz
Alpha: 7.5–12.5 Hz
  Alpha 1: 7.5–10 Hz
  Alpha 2: 10–12.5 Hz
Beta: 13–20 Hz
The sources, functions, and behavior of alpha and 
theta rhythms have been the subject of much theoretical 
and empirical research, but the detailed mechanics of these 
observed ﬁ  ndings remain far from being understood or agreed 
upon by researchers (Sadato et al 1998; Klimesch 1999; Liley 
et al 1999; Cantero et al 2000; Nunez 2000; Nunez et al 
2001). Alpha and theta EEG bands are probably the most 
extensively researched EEG spectrums in humans, and 
regardless of the confusion over the physiological brain 
events underlying these rhythms a few phenomenological 
properties of alpha and theta EEG rhythms have been well 
established. The alpha band power is the prominent EEG 
band of the normal awake human resting EEG and diminishes 
in amplitude with drowsiness and sleep onset (see Klimesch 
[1999] and Nunez et al [2001] for reviews). Theta rhythms 
also exhibit resting differences corresponding to arousal 
level, showing increased synchrony in states of decreased 
vigilance and diminished cognitive performance (Paus et al 
1997; Smit et al 2004). Upon mental exertion (as opposed 
to resting conditions) alpha rhythms desynchronize (reduce 
power), and theta rhythms synchronize, and it is thought 
that the magnitude of these changes is positively correlated 
with amount of mental exertion required of an individual 
in completing a mental task (Gevins et al 1997, 1998). It 
has been shown that more intelligent individuals display 
less alpha desynchronization in novel tasks than less gifted 
individuals, supporting the Neural Efﬁ  ciency Hypothesis, Neuropsychiatric Disease and Treatment 2007:3(3) 357
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which states that more efﬁ  cient information processing in the 
brains of more intelligent subjects results in the need for less 
mental effort than their average counterparts in solving the 
same problem (Jausovec 1996, 2000; Neubauer et al 2002; 
Grabner et al 2003). It has also been observed that in human 
adults intelligence is positively correlated with EEG alpha 
power in a simple awake resting condition (Jausovec 1996, 
2000; Doppelmayr et al 2002).
Caldwell et al (2000) studied the effects of modaﬁ  nil in 
six helicopter pilots kept awake for two 40-hour periods; in 
one period they received three 200-mg doses of modaﬁ  nil, 
and in the other they received placebo. Modaﬁ  nil treatment 
kept ﬂ  ight simulation performance near baseline, while 
ﬂ  ight simulation performance in the placebo condition was 
decreased by roughly 10%–20%. Modaﬁ  nil also showed 
decreased power in the delta and theta EEG bands under 
modaﬁ  nil versus placebo. There was little reported effect 
from modaﬁ  nil on alpha and beta band powers.
Chapotot et al (2003) studied the EEG effects of modaﬁ  nil 
and d-amphetamine compared to placebo on 64 hours of 
sustained wakefulness in 41 healthy volunteers. It was found 
that both modaﬁ  nil and d-amphetamine decreased power in 
the delta and theta 2 bands. D-amphetamine was shown to 
decrease power in the alpha 1 band, and modaﬁ  nil was shown 
to increase power in the alpha 1 band.
Saletu and colleagues published two papers examining 
EEG differences in narcoleptics and normal controls and the 
effects of modaﬁ  nil on local EEG differences of narcolep-
tics in a double-blind, placebo-controlled, crossover trial. 
Both studies compared EEG spectral power differences for 
16 narcoleptics and 16 normal controls in resting EEG. The 
second part of both studies involved placing the narcoleptic 
patients in a double-blind, placebo-controlled, crossover 
study of modaﬁ  nil consisting of two treatment periods 
each of three weeks separated by a 1-week washout phase 
and a measurement of EEG activity at the beginning and 
end of each treatment phase. Vigilant EEG was measured 
in the ﬁ  rst study but showed few differences between any 
of the groups, so it was not measured in the second study. 
The resting EEG, however, did show differences in the 
alpha 2, beta 1, beta 2, and beta 3 bands in both studies, 
with normal controls showing greater power in these bands 
than the narcoleptic patients, and the modaﬁ  nil-treated 
narcoleptic group showing greater power in these bands 
than the placebo-treated group. These results indicate that 
narcolepsy causes decreased alpha and beta activity, and 
modaﬁ  nil increases the activity seen in these bands (Saletu 
et al 2004, 2005).
Functional magnetic resonance imaging 
studies
Spence et al (2005) examined the acute effects of 100 mg 
of modaﬁ  nil on short term memory and cerebral blood ﬂ  ow 
(with fMRI) in 17 medication controlled schizophrenic 
patients using a double-blind, placebo-controlled, crossover 
design consisting of 2 trial days separated by one week. 
Subjects identiﬁ  ed the numbers 1–4 by pushing 1 of 4 but-
tons, and color coding told subjects whether they should 
identify the number currently on the screen or the number 
on the screen 2 numbers previously. They found that anterior 
cingulate activation increased in most subjects, and working 
memory improved in a minority of subjects, but no subjects 
with reduced anterior cingulated activation demonstrated 
improved working memory. A post-hoc analysis of the data 
also showed that those who improved on modaﬁ  nil had low 
baseline scores. These results indicated to the authors that low 
dose modaﬁ  nil may have an anterior cingulate cortex medi-
ated effect on working memory in impaired schizophrenics 
with particular characteristics.
Ellis et al (1999) used fMRI to examine auditory and vi-
sual cortical activation levels in 12 normal subjects and in 12 
narcoleptic subjects (not exposed to amphetamine for at least 
4 days) and the effects of 400 mg of modaﬁ  nil versus placebo 
in these two groups. They found no signiﬁ  cant differences 
in mean group cortical activations for narcoleptic subjects 
versus normal subjects. After administering modaﬁ  nil to 
8 subjects in each group and placebo to 4 in each group 
and waiting 13.25 or 18.25 hours, they observed cortical 
activation in response to visual and auditory stimuli with 
fMRI again. They found no signiﬁ  cant change in the mean 
activation due to modaﬁ  nil or placebo, but they found a strong 
negative correlation (auditory r = –0.74; visual r = –0.76) 
between cortical activation before modaﬁ  nil and cortical 
activation after modaﬁ  nil for individual subjects. The fact 
that modaﬁ  nil increased cortical activation in subjects with 
low cortical activation and decreased it in subjects with high 
cortical activation indicates that its effects are not unilateral 
but are a function of baseline cortical activation and its effects 
are modulatory and regulatory rather than augmentative.
Discussion of neurocognitive studies
The tendency of modaﬁ  nil to increase alpha power and de-
crease theta power (Caldwell et al 2000; Chapotot et al 2003; 
Saletu et al 2004, 2005) in human subjects is both consistent 
with modaﬁ  nil’s stimulant properties and suggestive that 
modaﬁ  nil improves brain function, an effect shown in the Neuropsychiatric Disease and Treatment 2007:3(3) 358
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Table 1 Summary of modaﬁ  nil effects
Neurocognitive aspects  + Accuracy  – Accuracy  + Speed  – Speed  No effect  May help in  
           cocaine  abuse
Working memory  1,2,8,9     11b 1,8,9,11  1,2,4,6,10c,12
Memory 1,2,7      2  1,9  1,3,4,8,10c,11
Attention/impule control  1,5a,6,7,9b,11,13,14     4,5a,7,9b,11,14b 1,9  1,2,3,4,10c,11  ■
Reasoning, learning, high   8,9,14b 4      1,3,4,6,10c,11  ■
level function
1) Turner et al (2003), 2) Muller et al (2004), 3) Randall et al (2003), 4) Randall et al (2004), 5) Randall et al (2005), 6) Walsh et al (2004), 7) Hart et al (2005), 8) Turner et al 
(2004b), 9) Turner et al (2004a), 10) Sevy et al (2005), 11) Randall et al (2005), 12) Chan et al (2006), 13) Gill et al (2006), 14) Killgore et al (2006).
aimprovement for lower IQ subjects, b400 mg dose showed effect, cSchizophrenic subjects controlled with atypical antipsychotics.
helicopter pilot study (Caldwell et al 2000) and in the cogni-
tive performance studies discussed below.
None of the studies regarding EEG changes from 
modaﬁ  nil that we found measured modaﬁ  nil’s effects on 
event-related EEG changes in instances of mental exertion, 
but modaﬁ  nil’s resting EEG proﬁ  le and stimulant proper-
ties do suggest that it would enhance mental performance, 
at least in individuals in the condition of sleep-deprivation, 
a common factor in stimulant abusers. A number of studies 
testing modaﬁ  nil’s effects on neurocognitive functioning 
tend to conﬁ  rm that modaﬁ  nil mildly enhances cognitive 
performance in healthy volunteers, especially with regards to 
executive function. These results are summarized in Tables 
1–3. There were two studies published by Randall et al that 
showed little or no signiﬁ  cant effect of modaﬁ  nil on neuro-
cognitive test performance in healthy individuals (Randall 
et al 2003, 2004), but a later review done by this group on 
their own research showed that modaﬁ  nil did improve neu-
rocognitive performance in average IQ subjects but not high 
IQ subjects (Randall et al 2005). The authors concluded that 
this indicates that modaﬁ  nil has limited cognitive enhancing 
effects in already high-performing well-rested individuals, 
but they did not consider ceiling effects in neurocognitive 
tests designed to measure cognitive impairment as some of 
the other studies did (Turner et al 2003; Muller et al 2004).
The effects of modaﬁ  nil on response latency as well as 
accuracy are also particularly telling. Modaﬁ  nil showed 
increased response latency in some cases, especially in TOL 
spatial planning task (Turner et al 2003, 2004a, b; Randall 
et al 2005), and modafinil generally caused decreased 
response latency in tests of attention and impulse control and 
improvements in tests of attention (Randall et al 2004, 2005a, 
b; Turner et al 2004a; Walsh et al 2004; Hart et al 2005; 
Gillet al 2006; Killgore et al 2006). Only one of the studies 
showing slowed response time in the TOL also showed an 
accuracy improvement due to modaﬁ  nil in this task (Turner 
et al 2003), but this may be due to ceiling effects as mentioned 
previously. These results indicate that modaﬁ  nil promotes 
impulse control and improves attention. Both of these effects 
are of value in stimulant abuse and addiction treatment. In 
all tasks in which a study showed that modaﬁ  nil increased 
speed of response, there was an observed increase in accuracy 
by at least one (possibly different) study and no observed 
decreases in accuracy, with the exception of the Stroop test 
for which total errors were near zero or equal to zero for 
all groups in the data shown. This shows that modaﬁ  nil did 
not increase speed of response at the cost of accuracy, but it 
increased accuracy while reducing information processing 
and response time, and this suggests that modaﬁ  nil may also 
enhance neural efﬁ  ciency.
It should also be noted that a number of studies examined 
the effects of modaﬁ  nil in patients with underlying neuro-
cognitive health deﬁ  cits and found no signiﬁ  cant effects in 
these populations. A double-blind, placebo-controlled trial 
testing the cognitive enhancing effects of 100 mg modaﬁ  nil 
in 10 medication stabilized schizophrenic patients versus 
placebo in 10 other medication stabilized schizophrenic 
patients showed almost no effect of modaﬁ  nil (Sevy et al 
2005). Two small independent studies of fatigued patients 
showed mixed neurocognitive effects of modaﬁ  nil and an 
inability of subjects to reliably distinguish between modaﬁ  nil 
and placebo (Randall et al 2005a; Chan et al 2006). All of 
these studies had major limitations, especially small sample 
size, and the 100 mg dose used in the study by Sevy et al 
may have been too low to have any effect. Nevertheless, 
future research endeavors may wish to investigate if there is a 
physiologic reason for the relative lack of effect of modaﬁ  nil 
in these patient populations.
Although only one study with signiﬁ  cant limitations tested 
the effects of modaﬁ  nil on humor appreciation (Killgore 
et al 2006), this topic deserves particular attention, because 
humor appreciation is a very complex neural task requiring 
frontal lobe function and integrative information processing 
between numerous cortical and subcortical brain regions Neuropsychiatric Disease and Treatment 2007:3(3) 359
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(Shammi and Stuss 1999; Goel and Dolan 2001; Mobbs 
et al 2003; Moran et al 2004). This test compared the effects 
of modaﬁ  nil to caffeine and amphetamine in not only humor 
appreciation, but also PVT performance and Stanford Sleepi-
ness Test Score. While the modaﬁ  nil group had only the 
second best PVT scores and the worst Stanford Sleepiness 
Test scores, they had the best humor appreciation scores. 
This suggests that modaﬁ  nil’s mechanism is not limited to 
actions on wake-promoting brain regions, because caffeine 
and amphetamine must have stimulated those regions even 
more potently in this study than modaﬁ  nil while producing 
less effect on humor appreciation. The results of this study 
combined with studies of the brain regions mediating humor 
(Shammi and Stuss 1999; Goel and Dolan 2001; Mobbs et al 
2003; Moran et al 2004) provide further support to the idea 
that modaﬁ  nil improves whole-brain function. 
We found only two neuroimaging studies examining the 
effects of modaﬁ  nil (Ellis et al 1999; Spence et al 2005) both 
of which used BOLD fMRI to observe event-related circula-
tory changes in the brain. These two studies are very different 
in their procedure and population, but they both showed that 
modaﬁ  nil appears to modulate rather than unilaterally alter 
event-related cortical blood ﬂ  ow changes, for in both stud-
ies modaﬁ  nil’s effect on event-related cortical blood ﬂ  ow 
changes is negatively correlated to baseline event-related 
cortical blood ﬂ  ow change. Notably, the study involving 
schizophrenic subjects measured event related changes in a 
working memory task, while the study comparing narcoleptic 
and normal subjects measured event-related changes during 
sensory stimulation. Modaﬁ  nil’s effects on regional activa-
tion appear to be dependent on baseline activation in both par-
adigms, increasing BOLD signal in those with low baseline 
event related BOLD changes and decreasing BOLD signal 
in those with high baseline event related BOLD changes. In 
contrast to this, the stimulant amphetamine simply increases 
blood ﬂ  ow changes in cortical activation (Uftring et al 2001). 
Thus, these studies provide further evidence that modaﬁ  nil’s 
stimulant properties are the result of enhanced whole brain 
function rather than localized neural excitation.
Unexplored mechanisms of modaﬁ  nil
The current body of research presented above appears to be 
focused on investigating only extracellular localized sites of 
action for modaﬁ  nil in the brain, despite the fact that there 
is little evidence that modaﬁ  nil’s primary mechanism of 
action would be limited to an extracellular site or a particular 
single brain region. In fact many of these studies provide 
evidence to the contrary, showing that modaﬁ  nil does not 
act on the extracellular targets that would be most plausible 
in mediating the effects of modaﬁ  nil in the diseases and 
conditions studied. There are, however, a few studies that 
investigate effects of modaﬁ  nil on processes that are possibly 
or even likely intracellularly mediated, and in each of these 
studies an effect due to modaﬁ  nil is found (Pierard et al 1995; 
Antonelli et al 1998; Ferraro et al 2000, 2001; Jenner et al 
2000; Xiao et al 2004). Though an extracellular mechanism 
of action cannot be ruled out, these studies taken together 
suggest that perhaps modaﬁ  nil targets an intracellular protein 
or receptor rather than an extracellular site.
A number of plausible but uninvestigated sites of action 
for modaﬁ  nil, both intracellular and extracellular, remain to 
be studied to explain its stimulant effects and its neuropro-
tective effects. While modaﬁ  nil has been shown to have no 
binding afﬁ  nity to a number of ion channels (Mignot et al 
1994), we found no reports examining modaﬁ  nil’s afﬁ  nity for 
sodium channels or P/Q or R calcium channels. Modaﬁ  nil’s 
ability to enhance neurotransmitter release without actually 
stimulating neurons has led to the suggestion of enhanced 
neuroelectrosecretory coupling as a mechanism of modaﬁ  nil 
(Ferraro et al 2000), and the ion channels above have a 
potential here as a direct target of the action of modaﬁ  nil. 
Altered depolarization requirements of neurons via changes 
in sodium homeostasis, or enhanced calcium inﬂ  ux could 
explain increased neurotransmitter release (which is calcium 
dependent) when a neuron is stimulated.
It is also worth noting that while modaﬁ  nil is chieﬂ  y 
thought of as a stimulant, it has clearly demonstrated both 
wake-promoting and neuroprotective effects in preclinical 
studies, yet no previous papers to our knowledge have 
reported any attempt to integrate these ﬁ  ndings or to ﬁ  nd 
a common site of action that could mediate both of these 
effects. If modaﬁ  nil works through either of the ﬁ  rst two 
mechanisms mentioned above (ie, via alterations in sodium 
or calcium channel function), this could explain modaﬁ  nil’s 
stimulant effects, but these mechanisms do not lend them-
selves well to explaining its neuroprotective effects. The 
neuroprotective and wake-promoting effects may be the 
result of different mechanisms of action, but recent research 
shows that sleep induction and neurodegeneration may have 
common or related pathways, which would indicate the 
potential for a single site of action to be responsible for a 
drug’s ability to inhibit both processes.
It has been suspected for a long time, and it is generally 
agreed now that cellular mitochondria, calcium homeostasis, 
and oxidative stress play important roles in neurodegenera-
tion. Research also suggests that oxidative stress and neural Neuropsychiatric Disease and Treatment 2007:3(3) 362
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metabolic function, such as the availability of high energy 
metabolic substrates including creatine, are important me-
diators of arousal state and cognitive functions (McMorris 
et al 2006). A report showing that reactive oxygen species 
increased adenosine levels and induced slow-wave sleep 
suggests that sleep may function in part to allow the reactive 
oxygen species scavenging system to restore neurochemical 
redox states (Ikeda et al 2005). There has also been research 
showing that neurons of the neocortex and substantia nigra 
have ATP-sensitive potassium channels (KATP-channels) that 
suppress neuron ﬁ  ring and neurotransmitter release in states 
of reduced ATP or elevated H2O2. The effect of these channels 
on neuron ﬁ  ring rate in nigral dopamine neurons is such that 
administration of the KATP-channel antagonist glibenclamide 
at a 100 nM concentration was able to increase neuron ﬁ  ring 
rate by 34% (Garcia de Arriba et al 1999; Avshalumov et al 
2005). KATP-channel activity also appears to be increased by 
extracellular adenosine via adenosine A1 receptor stimulation 
(Heurteaux et al 1995). Therefore, enhanced mitochondrial 
ATP production, reduced production of H2O2, or reduced 
reactive oxygen species production would be expected to 
increase neurotransmitter release upon neuron stimulation 
via reduction in KATP-channel activity. 
Any mechanism involving improved mitochondrial func-
tion or free-radical scavenging could, therefore, explain how 
modaﬁ  nil enhances neurocognitive function and bolsters 
serotonin release without stimulating serotonin release on its 
own (Ferraro et al 2000, 2001, 2005). While no antioxidant 
or mitochondrial effects of modaﬁ  nil have been reported in 
the context of its ability to promote wakefulness or enhance 
neurotransmitter release, it has been shown that modaﬁ  nil 
does have an antioxidant effect that appears to mediate its 
neuroprotective actions in MPTP-induced neurodegeneration 
(Xiao et al 2004). The site of action mediating this effect has 
not yet been elucidated, and there are a number of plausible 
intracellular targets which we explore here that would explain 
both modaﬁ  nil’s stimulant effects, neuroprotective effects, 
and perhaps its effects as a therapeutic tool in addiction.
  In summary, the bulk of research into modaﬁ  nil’s 
wake-promoting mechanism has focused mostly on pos-
sible extracellular activities of modaﬁ  nil. We propose that 
more work be done on examining potential intracellular 
mechanisms of modaﬁ  nil and ﬁ  nding a point of convergence 
of modaﬁ  nil’s stimulant and neuroprotective effects. It is 
likely that modaﬁ  nil both enhances cellular metabolism and 
reduces free-radicals in neurons (Pierard et al 1995; Xiao 
et al 2004). Reduction in brain oxidation or an increase 
in cortical creatine could promote vigilance (Ikeda et al 
2005; McMorriset al 2006), and each effect can increase 
neurotransmitter release by reducing inhibitory KATP-
channel activity. Thus, through any disruption in the positive 
feedback loop of increased free-radical production and 
reduced ATP production modaﬁ  nil could potentially exert 
its neuroprotective and wake-promoting effects. 
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